Hepatic Manifestations and Effect of Long COVID-19 on Patients With Chronic Liver Disease
Study Details
Study Description
Brief Summary
To measure the frequency of persistent liver dysfunction (raised liver enzymes, serum albumin, prothrombin time, etc) in recovered COVID -19 patients.
To compare the hepatic manifestations in post COVID -19 patients with and without liver disease
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The digestive tract, particularly the liver, has recently been reported to be affected by SARS-CoV-2. Although abnormal liver enzymes were regularly described as an extra-pulmonary clinical feature, and almost one half of patients experienced grades of hepatic injury. liver damage in patients with SARS infections was primarily manifested in the mild and moderate elevation of alanine and/or aspartate aminotransferases (ALT and AST) with some degree of hypoalbuminemia and hyperbilirubinemia during the early stage of the illness.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| control group non cirrhotic compare liver function 1m after COVID-19 and that at beginning of infection |
Diagnostic Test: liver function , prothrombin time , INR , US .
analytic
|
| cirrhotic patients compare liver function 1m after COVID-19 and that at beginning of infection |
Diagnostic Test: liver function , prothrombin time , INR , US .
analytic
|
Outcome Measures
Primary Outcome Measures
- to evaluate the long term effect of COVID 19 on the liver [1 month]
to evaluate the changes in liver function (bilirubin ,liver enzymes , albumin , prothrombin time and INR in patients post COVID_19
Secondary Outcome Measures
- : Effect of COVID 19 on diseased liver [1 month]
to evaluate the changes in liver function(bilirubin , liver enzymes , albumin , prothrombin time , INR) in cirrhotic post COVID_19
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients previously diagnosed by COVID 19 eg : PCR and / or HRCT chest, lab of more than 1 month duration.
Exclusion Criteria:
-
Patients less than 18 y.
-
Patients with acute COVID 19.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558-570. doi: 10.1080/22221751.2020.1736644. eCollection 2020. Review.
- Sultan S, Lim JK, Altayar O, Davitkov P, Feuerstein JD, Siddique SM, Falck-Ytter Y, El-Serag HB; AGA Institute. Electronic address: ewilson@gastro.org. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology. 2020 Aug;159(2):739-758.e4. doi: 10.1053/j.gastro.2020.03.072. Epub 2020 Apr 1. Review.
- Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci. 2020 Mar 15;16(10):1686-1697. doi: 10.7150/ijbs.45472. eCollection 2020. Review.
- liver in COVID-19